GlaxoSmithKline: Rotarix correction; set to settle around $1 billion in Avandia law suits; names drug discovery chief

12 May 2010

In the story published by The Pharma Letter yesterday, relating to the US Coalition for Vaccine Safety's call for an immediate suspension of all contaminated rotavirus vaccines, it was erroneously stated that DNA from pig virus PCV-2 was identified in GlaxoSmithKline's Rotarix, whereas in fact it was only PCV-1. We apologize for the error.

Diabetes drug settlement

In a further move relating to allegations that GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) increased the risk of heart attack - and a critical US Senate Finance Committee report which claimed that the company knew of the risks (TPLs passim), a report this week by the Bloomberg news service said the company has agreed to pay around $60 million to settle some 700 law suits brought by patients who claimed the UK drug giant's diabetes drug had caused heart attacks and strokes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK